1380347-94-3

Basic information

• Product Name: 5-aMino-3-benzyl-1-Methyl-1H-pyrazole-4-carbonitrile
• Synonyms: 5-aMino-3-benzyl-1-Methyl-1H-pyrazole-4-carbonitrile
• CAS NO: 1380347-94-3
• Molecular Formula: C₁₂H₁₂N₄
• Molecular Weight: 212.25048
• Mol File: 1380347-94-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-aMino-3-benzyl-1-Methyl-1H-pyrazole-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-aMino-3-benzyl-1-Methyl-1H-pyrazole-4-carbonitrile(1380347-94-3)
• EPA Substance Registry System: 5-aMino-3-benzyl-1-Methyl-1H-pyrazole-4-carbonitrile(1380347-94-3)

Safety Data

• Hazardous Substances Data: 1380347-94-3(Hazardous Substances Data)

Upstream product

• 42754-59-6 2-(1-Methoxy-2-phenylethylidene)malononitrile 
• 60-34-4 methylhydrazine 

Downstream Products

• 1268522-40-2 5-amino-3-benzyl-1-methyl-1H-pyrazole-4-carboxylic acid 
• 1380347-95-4 3-benzyl-1-methyl-5-nitro-1H-pyrazole-4-carboxylic acid 
• 1380347-96-5 (3-benzyl-1-methyl-5-nitro-1H-pyrazol-4-yl)methanol 
• 1380347-97-6 3-benzyl-4-(bromomethyl)-1-methyl-5-nitro-1H-pyrazole 
• 1380347-98-7 tert-butyl 3-(3-benzyl-1-methyl-5-nitro-1H-pyrazol-4-yl)-N-(diphenylmethylene)-L-alaninate 
• 1380348-03-7 2,2,2-trifluoroethyl 3-(3-benzyl-1-methyl-5-nitro-1H-pyrazol-4-yl)-N-(tert-butoxycarbonyl)-L-alaninate 
• 1380347-92-1 (5S)-5-amino-3-benzyl-7-hydroxy-1-methyl-1,4,5,7-tetrahydro-6H-pyrazolo[34-b]pyridin-6-one 
• 1380481-73-1 C₁₄H₁₆N₄O₄ 
• 1380348-01-5 3-(3-benzyl-1-methyl-5-nitro-1H-pyrazol-4-yl)-N-(tert-butoxycarbonyl)-L-alanine 
• 1380348-05-9 PF-04859989 

Relevant articles and documents

SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS

The present application relates to substituted fused heteroaryl and heterocyclic compounds, useful as nicotinamide adenine dinucleotide phosphate oxidase inhibitors (NADPH oxidase inhibitors), processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by NADPH oxidase. (Formula I)

KAT II INHIBITORS

Compounds of Formula I: (I) wherein X, Y, Z, R 1, R 2, R 3, R 4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive 5 deficits associated